A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

clipboard-pencil

About the study

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Have type 2 diabetes
  2. Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
  3. Have a BMI ≥ 27 kg/m2
  4. Have a stable body weight (<5% body weight change) for 90 days prior to screening

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  2. Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  3. Have type 1 diabetes
  4. Have taken any of the following antihyperglycemic medications within 90 days before screening:

  1. amylin analogs
  2. glucagon-like peptide-1 (GLP-1) receptor agonists
  3. glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
  4. insulin
  5. Have had within 90 days prior to screening:

  1. heart attack
  2. stroke
  3. coronary artery revascularization
  4. unstable angina, or
  5. hospitalization due to congestive heart failure
  6. Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
  7. Have taken medications or alternative remedies intended for weight loss within 90 days of screening

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 317-615-4559Email iconEmail Study Center

Study Details


Contition
Overweight,Obesity
Age
18+
Phase
PHASE3
Participants Needed
1035
Est. Completion Date
Feb 29, 2028
Treatment Type
INTERVENTIONAL

Sponsor
Eli Lilly and Company
ClinicalTrials.gov NCT Identifier
NCT07282600
Study Number
J3R-MC-YDAF

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?